Form 8-K - Current report:
SEC Accession No. 0001193125-25-111635
Filing Date
2025-05-02
Accepted
2025-05-02 16:15:44
Documents
14
Period of Report
2025-04-28
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d807781d8k.htm   iXBRL 8-K 41217
2 EX-10.1 d807781dex101.htm EX-10.1 636005
  Complete submission text file 0001193125-25-111635.txt   924721

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA me1-20250428.xsd EX-101.SCH 2873
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE me1-20250428_lab.xml EX-101.LAB 17993
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE me1-20250428_pre.xml EX-101.PRE 11277
17 EXTRACTED XBRL INSTANCE DOCUMENT d807781d8k_htm.xml XML 3684
Mailing Address 870 MARKET STREET ROOM 415 SAN FRANCISCO CA 94102
Business Address 870 MARKET STREET ROOM 415 SAN FRANCISCO CA 94102 (650) 938-6300
23andMe Holding Co. (Filer) CIK: 0001804591 (see all company filings)

EIN.: 871240344 | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-39587 | Film No.: 25908749
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)